| All Releases |
|---|
 |
Announcement by Progenics Pharmaceuticals under Nasdaq Marketplace Rules
Dec 11, 2008
|
12.5 KB
|
| |
TARRYTOWN, N.Y., Dec 11, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that it
has received a Nasdaq Staff Deficiency Letter indicating that it fails
to comply with Nasdaq's audit committee requirements. As a result of Mr.
Paul F. Jacobson's previously-announced resignation from the C...
|
|
|
Wyeth and Progenics Announce Positive Outcome of Phase 3 Clinical Study of Subcutaneous RELISTOR for Opioid-Induced Constipation in Patients with Chronic Non-Cancer Pain
Nov 26, 2008
|
19.7 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Nov 26, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics
Pharmaceuticals, Inc. (Nasdaq: PGNX) announced today that a phase 3
clinical study investigating RELISTOR(R) (methylnaltrexone
bromide) subcutaneous injection to treat opioid-induced cons...
|
|
|
Progenics Announces Wyeth Has Received Relistor Approval in Australia
Nov 17, 2008
|
14.3 KB
|
| |
Tarrytown, NY, November 17, 2008 -Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced the Therapeutic Goods Administration (TGA) division of the Australian Government has approved the registration of RELISTOR® (methylnaltrexone bromide 12mg/0.6ml solution for injection) for the treatment of opioid-induced constipation (OIC...
|
|
|
Progenics Reports Third Quarter 2008 Financial Results and Corporate Updates
Nov 10, 2008
|
20.1 KB
|
| |
TARRYTOWN, N.Y., Nov 10, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the third quarter and nine months ended September 30, 2008.
Revenues for the third quarter totaled $17.5 million, compared to $17.0 million for the same period of 2007. For the nine months ended September...
|
|
|
Progenics Selects Small-Molecule Hepatitis C Drug Candidate for Clinical Development
Nov 4, 2008
|
14.7 KB
|
| |
SAN FRANCISCO & TARRYTOWN, N.Y., Nov 04, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the selection of a proprietary small-molecule drug candidate, designated PRO 206, for clinical development as a treatment of hepatitis C virus (HCV) infection. Pre-clinical results supporting the development of PRO 206 wer...
|
|
|
Progenics Reports Positive Interim Phase 2 Results for Two Dosage Forms 0f Novel HIV Therapy PRO 140
Oct 26, 2008
|
227.1 KB
|
| |
Washington, DC and Tarrytown, NY - October 26, 2008 - Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced positive interim results from two separate phase 2 clinical trials of PRO 140 for the treatment of HIV infection. Both intravenous and subcutaneous forms of PRO 140, a novel viral-entry inhibitor, exhibited potent and prolo...
|
|
|
Progenics Pharmaceuticals and Ono Pharmaceutical Announce Agreement to Develop and Commercialize RELISTOR in Japan
Oct 16, 2008
|
16.2 KB
|
| |
TARRYTOWN, N.Y., Oct 16, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Ono Pharmaceutical Co., Ltd., Osaka, Japan (OSE-TYO: 4528) today announced an exclusive license agreement under which Ono has acquired the rights to RELISTOR(R) (methylnaltrexone bromide) in Japan, where it plans to develop and commercialize the U.S....
|
|
|
Progenics Announces Progress and Presentations in HIV Therapy Program
Oct 2, 2008
|
18.0 KB
|
| |
TARRYTOWN, N.Y., Oct 02, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the completion of enrollment in two, phase 2 clinical studies of PRO 140, an investigational drug that is being developed for treatment of human immunodeficiency virus (HIV) infection. The phase 2 studies are separately evaluating intrave...
|
|
|
Progenics Initiates Phase 1 Clinical Study of Targeted Therapy for Prostate Cancer
Sep 8, 2008
|
18.7 KB
|
| |
TARRYTOWN, N.Y., Sep 08, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the initiation of a phase 1 dose-escalation clinical study of its prostate-specific membrane antigen (PSMA) antibody-drug conjugate (ADC). PSMA ADC is an investigational therapy that combines a prostate-cancer antibody with a cancer drug....
|
|
|
Progenics Pharmaceuticals Reports Second Quarter 2008 Results
Aug 8, 2008
|
21.7 KB
|
| |
TARRYTOWN, N.Y., Aug 08, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the second quarter and first half of 2008.
Revenues for the second quarter ended June 30, 2008 totaled $28.6 million compared to $25.5 million for the same quarter in 2007. For the first half of 2008, Pro...
|
|
|
Wyeth and Progenics Receive Approval from European Commission for RELISTOR for Opioid-Induced Constipation in Advanced Illness Patients
Jul 3, 2008
|
18.4 KB
|
| |
COLLEGEVILLE, Pa., & TARRYTOWN, N.Y., Jul 03, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received marketing approval for RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection from the European Commission. RELISTO...
|
|
|
New England Journal Of Medicine Publishes Results From A Relistor Phase 3 Clinical Study
May 28, 2008
|
20.0 KB
|
| |
Collegeville, Pa., and Tarrytown, N.Y., May 28, 2008 - Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced the publication of results from a pivotal phase 3 trial of RELISTORTM (methylnaltrexone bromide) subcutaneous injection in the May 29, 2008 issue of the New En...
|
|
|
Wyeth and Progenics Announce Preliminary Clinical Trial Results for RELISTOR Oral and Intravenous Formulations
May 22, 2008
|
20.5 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., May 22, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced preliminary results from two clinical trials conducted with investigational oral and intravenous formulations of RELISTOR(TM) (methylnaltrexone bromide).
...
|
|
|
CORRECTING and REPLACING Progenics Pharmaceuticals Reports First Quarter 2008 Results
May 9, 2008
|
18.8 KB
|
| |
TARRYTOWN, N.Y., May 09, 2008 (BUSINESS WIRE) -- The second bullet point under Recent Highlights should read: The FDA approval of RELISTOR for subcutaneous use triggered a $15 million milestone payment from Wyeth to Progenics. (sted: from Progenics to Wyeth.)
PROGENICS PHARMACEUTICALS REPORTS FIRST QUARTER 2008 RESULTS
Progenics Pharmaceuti...
|
|
|
Progenics Pharmaceuticals Reports First Quarter 2008 Results
May 9, 2008
|
18.6 KB
|
| |
TARRYTOWN, N.Y., May 09, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced its results of operations for the quarter ended March 31, 2008.
Revenues for the quarter totaled $14.8 million compared to revenues of $17.6 million for the same period in 2007. Revenues primarily reflect reimbursement by the Company'...
|
|
|
Progenics Pharmaceuticals to Host Conference Call Tomorrow at 10:00 AM Eastern Time to Discuss the Approval of RELISTOR (Methylnaltrexone Bromide)
Apr 24, 2008
|
11.4 KB
|
| |
TARRYTOWN, N.Y., Apr 24, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) will hold a conference call tomorrow at 10:00 AM Eastern Time to discuss the U.S. Food and Drug Administration's approval of RELISTOR(TM) (methylnaltrexone bromide) for subcutaneous injection. RELISTOR is indicated for the treatment of opioid-induced con...
|
|
|
Progenics Board Approves $15 Million Share Repurchase Program
Apr 24, 2008
|
13.9 KB
|
| |
TARRYTOWN, N.Y., Apr 24, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) today announced that its Board of Directors has approved a share repurchase program to acquire up to $15 million of its outstanding common shares.
Funding for the repurchase program will come from the $15 million milestone payment Progenics will rece...
|
|
|
Progenics and Wyeth Announce FDA Has Approved RELISTOR
Apr 24, 2008
|
19.1 KB
|
| |
TARRYTOWN, N.Y. & COLLEGEVILLE, Pa., Apr 24, 2008 (BUSINESS WIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) and Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), today announced that the U.S. Food and Drug Administration (FDA) has approved RELISTOR(TM) (methylnaltrexone bromide) subcutaneous injection for the treatment of opioid-induc...
|
|
|
Wyeth and Progenics Receive Positive Opinion From European Committee for RELISTOR for the Treatment of Opioid-Induced Constipation in Advanced-Illness Patients
Apr 24, 2008
|
14.8 KB
|
| |
COLLEGEVILLE, Pa. and TARRYTOWN, N.Y., April 24, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that the companies have received a positive opinion for RELISTOR™ (methylnaltrexone...
|
|
|
Wyeth and Progenics Announce RELISTOR Receives Canadian Marketing Approval
Apr 1, 2008
|
18.2 KB
|
| |
COLLEGEVILLE, Pa. & TARRYTOWN, N.Y., Apr 01, 2008 (BUSINESS WIRE) -- Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), and Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX), today announced that Wyeth has received marketing approval from Health Canada, the Canadian Regulatory Agency, for RELISTOR(TM) (methylnaltrexone bromide injection) for subc...
|
|
|
